The polymyalgia rheumatica and giant cell arteritis clinic nurse’s communication challenge
Polymyalgia rheumatica and giant cell arteritis occupy a unique position in outpatient rheumatology: they are the most common inflammatory rheumatic diseases of older adults, they are dramatically responsive to treatment, and they produce three distinct communication challenges that are all determined by how the disease and its treatment look to the patient rather than how the underlying pathophysiology works. The first challenge is the PMR prednisone paradox: the rapid and near-complete pain relief that prednisone produces within days of starting — the same rapid response that is part of the diagnostic criteria for PMR — is the single most potent driver of premature discontinuation, because a patient who was severely disabled by bilateral shoulder and hip stiffness and is now fully functional at two weeks naturally concludes the disease is over, not that the medication is actively suppressing it every day. The second challenge is the silent GCA transition: the symptoms that distinguish a GCA emergency from an ordinary headache — temporal location, scalp tenderness on combing, jaw claudication while eating — are not symptoms a patient or family member automatically volunteers unless they are asked specifically, and the English-language clinical interview that elicits these symptoms relies on the patient understanding concepts like “jaw claudication” that have no obvious Spanish equivalent in the lay vocabulary; the nurse who can ask the three targeted questions in Spanish is the barrier between a potentially devastating vision loss and a preserved visual field. The third challenge is the CRP-tocilizumab dissociation: tocilizumab normalizes CRP completely within two weeks of starting by blocking the IL-6 receptor, not by suppressing the granulomatous inflammation in the vessel wall, and every patient on tocilizumab will have a normal CRP by the time of the first follow-up visit; explaining why a normal CRP on tocilizumab is a sign the drug is working rather than a sign the disease has resolved is the most pharmacologically complex nurse-patient communication challenge in the PMR-GCA clinic.
Three conversations from the polymyalgia rheumatica and giant cell arteritis clinic:
Scenario 1: María Guadalupe Ríos-Espinoza — 67 years old, Phoenix, Arizona
María Guadalupe Ríos-Espinoza was a sixty-seven-year-old retired school administrator in Phoenix who had been in excellent health until four months before her rheumatology visit. The onset was gradual but unmistakable: bilateral shoulder girdle stiffness that was worst in the first hour after waking, progressing over six weeks to a point where she could not lift her arms above shoulder height, could not reach the top shelf of the kitchen cabinet, and needed her husband Roberto to help her get her coat on in the morning. The stiffness extended to the hip girdles: standing from a seated position required several minutes and significant effort; climbing stairs had become painful enough that she was taking the elevator at the shopping center. Fatigue was significant. She had lost four kilograms over three months without dieting.
Her primary care physician had done standard labs: CBC (normal); comprehensive metabolic panel (normal); TSH (normal, ruling out hypothyroidism as a cause of diffuse stiffness); rheumatoid factor (negative); anti-CCP (negative); ANA (negative); ESR 88 mm/hr (markedly elevated; normal for age would be approximately 27 mm/hr in a woman her age); CRP 6.4 mg/dL (markedly elevated; normal <0.5 mg/dL). No joint swelling. No synovitis. No peripheral arthritis. Temporal arteries were not tender on palpation. No headache. No scalp tenderness. No jaw claudication. No visual symptoms. The clinical picture was classic PMR.
She was referred to rheumatology. At the diagnostic visit, clinical nurse Claudia Ramírez-Flores conducted the initial assessment. The rheumatologist confirmed the diagnosis: bilateral shoulder girdle stiffness with morning stiffness exceeding ninety minutes, bilateral hip girdle aching and stiffness, elevated ESR and CRP, negative rheumatoid markers, age sixty-seven (PMR essentially does not occur before age fifty, and the incidence increases steeply with each decade thereafter), no features of peripheral inflammatory arthritis or cranial GCA. A temporal artery biopsy was not indicated in the absence of any cranial GCA symptoms. The ACR/EULAR 2015 diagnostic criteria for PMR were fully met.
Nurse Ramírez-Flores spent the post-visit time with María Guadalupe and Roberto explaining the diagnosis, the treatment plan, and — critically — the expected trajectory of response and what it meant. The rheumatologist had started prednisone fifteen milligrams per day. The nurse explained that prednisone for PMR typically worked very fast — within twenty-four to seventy-two hours, most patients felt a fifty to seventy percent improvement in their stiffness and pain; within two weeks, many felt entirely normal. She made the crucial next point explicitly: this dramatic improvement did not mean the disease was cured. It meant the prednisone was working. The difference between “the medication is working” and “the disease is resolved” was the hinge point on which the entire treatment plan depended. She said it in Spanish, directly and without softening it:
“La prednisolona no cura la polimialgia — la controla cada día que usted la toma. Cuando el dolor desaparezca en unos días — y va a desaparecer rápido, eso es normal con esta enfermedad — eso no significa que la polimialgia se fue. Significa que el medicamento está bloqueando la inflamación. Si para el medicamento porque se siente bien, la inflamación va a volver en dos o tres semanas. El tratamiento correcto es doce a dieciocho meses, bajando la dosis muy lentamente. Si para sola, tendremos que empezar todo de nuevo.”
(Prednisone does not cure polymyalgia — it controls it every day you take it. When the pain disappears in a few days — and it will disappear quickly, that is normal with this disease — that does not mean the polymyalgia is gone. It means the medication is blocking the inflammation. If you stop the medication because you feel well, the inflammation will return in two to three weeks. The correct treatment is twelve to eighteen months, lowering the dose very slowly. If you stop on your own, we will have to start all over.)
She documented this conversation in the chart. She gave María Guadalupe and Roberto a written Spanish-language handout explaining the taper schedule and the GCA warning symptoms. The eight-week follow-up appointment was scheduled.
At forty-eight hours after starting prednisone, María Guadalupe called the clinic to report that she felt sixty percent better. At two weeks, she reported she felt entirely normal — no shoulder stiffness, no hip pain, back to full activity. The clinic called to confirm she was tolerating prednisone and to remind her of the eight-week visit.
The eight-week follow-up call went unanswered. The nurse called again three days later. María Guadalupe answered and said she had been meaning to call. She had stopped prednisone four weeks earlier — at the six-week mark — because she felt completely well and did not want to take steroids longer than necessary. She had developed bilateral shoulder stiffness again about two weeks after stopping. It was now worse than before the first visit, and the hip stiffness had returned. She had been hoping it would resolve on its own.
Nurse Ramírez-Flores scheduled an urgent visit for that week. Labs confirmed relapse: ESR 94 mm/hr, CRP 7.1 mg/dL, both higher than at initial presentation. María Guadalupe was distressed — she had felt so well, and she had specifically wanted to avoid long-term steroid use.
The nurse revisited the mechanism, this time with the context of what had just happened to reinforce the explanation. Prednisone worked on PMR by entering the cells producing the inflammatory signals — primarily macrophages and dendritic cells in the bursa walls around her shoulder and hip joints — and blocking the proteins inside those cells that would otherwise turn on the genes for IL-6 and other inflammatory signals. As long as prednisone was blocking those proteins every day, the inflammatory signals stayed low, the bursae stayed quiet, and she had no pain. The moment she stopped prednisone, those blocking proteins were no longer occupied; the cells in the bursae resumed producing IL-6 and the other signals; the bursae became inflamed again; and the pain came back. There had been no permanent damage done to the bursal cells by the first prednisone course; they were simply resumed their inflammatory activity when the suppression was removed. This was entirely predictable — and it was why the nurse had explained at the very first visit that the treatment needed to continue for twelve to eighteen months.
“Señora Guadalupe, lo que pasó es exactamente lo que explicamos en la primera cita: la prednisolona estaba bloqueando la inflamación cada día que la tomaba. Al pararla, las células que producen la inflamación en las bolsas de los hombros y las caderas retomaron su actividad. Eso no significa que usted hizo algo mal — es la biología de la enfermedad. Lo que tenemos que hacer ahora es reiniciar la prednisolona y seguir un plan de reducción muy gradual esta vez, con visitas más frecuentes para asegurarnos de que el dolor no regrese. El objetivo es controlar la inflamación con la dosis más baja posible durante el tiempo necesario — no con la dosis más alta durante el menor tiempo posible.”
(Mrs. Guadalupe, what happened is exactly what we explained at the first visit: the prednisone was blocking the inflammation every day you took it. By stopping it, the cells that produce the inflammation in the bursae of the shoulders and hips resumed their activity. That does not mean you did anything wrong — it is the biology of the disease. What we need to do now is restart prednisone and follow a very gradual reduction plan this time, with more frequent visits to make sure the pain does not return. The goal is to control the inflammation with the lowest possible dose for the necessary time — not with the highest dose for the least time.)
Prednisone was restarted at fifteen milligrams per day. At three weeks: ESR 22, CRP 0.4, full shoulder and hip mobility restored. A structured taper plan was documented: fifteen milligrams per day for four weeks; then twelve-point-five milligrams per day for four weeks; then ten milligrams per day for four weeks; then nine milligrams per day for four weeks; then eight milligrams per day for four weeks; continuing to reduce by one milligram every four to eight weeks guided by symptoms and inflammatory markers. Target: prednisone five milligrams per day at nine months; prednisone zero at approximately eighteen months from restart, pending ESR and CRP remaining suppressed. Additional care: calcium one thousand two hundred milligrams per day and vitamin D two thousand international units per day were started given the anticipated prolonged prednisone course; dual-energy X-ray absorptiometry was ordered to establish a bone density baseline and bisphosphonate therapy was considered. María Guadalupe received the contact number to call within twenty-four hours if shoulder or hip stiffness returned on the taper, or if any of the four GCA warning symptoms appeared.
Scenario 2: Aurelio Martínez-Gutiérrez — 72 years old, Houston, Texas
Aurelio Martínez-Gutiérrez was a seventy-two-year-old retired high school teacher in Houston who had been diagnosed with polymyalgia rheumatica eight months earlier. His presentation had been typical: bilateral shoulder girdle stiffness, morning stiffness lasting more than an hour, bilateral hip pain, ESR seventy-four mm/hr, CRP five-point-one mg/dL; negative RF, ANA, and anti-CCP; no cranial GCA symptoms; temporal arteries non-tender and normal on palpation. He had been started on prednisone fifteen milligrams per day with an excellent response: pain resolving within four days, full mobility by two weeks, ESR and CRP normalizing by month two. He had been on a structured taper and was currently at prednisone seven-point-five milligrams per day, stable for four months, with ESR fourteen mm/hr and CRP 0.3 mg/dL.
On a Monday morning, his wife Sofía called the clinic. She explained to the front-desk medical assistant that Aurelio had had a strong headache since Saturday and she was wondering if she should worry about it. The front-desk medical assistant, not knowing the specific significance of new headache in a PMR patient, noted the call and suggested Tylenol for now and to call back if it got worse, or to go to urgent care if the pain was very severe.
Clinic nurse Patricio Salinas-Ramírez reviewed the message board that afternoon and saw the note. He knew that Aurelio had PMR and was on a steroid taper. New headache in a PMR patient was not a routine symptom — it was a sentinel symptom for GCA transition. He called Sofía back within thirty minutes.
“Señora Sofía, soy Patricio, enfermero de la clínica de reumatología. Le llamo porque el señor Aurelio tiene polimialgia reumática, y con esa enfermedad necesitamos hacer tres preguntas específicas cuando hay un dolor de cabeza nuevo. ¿Me permite hacerle las preguntas rápido?”
Sofía: “Sí, claro, con mucho gusto.”
“Primera pregunta: ¿el dolor de cabeza está en las sienes — a los lados de la cabeza, cerca de las orejas y donde nace el pelo?”
Sofía: “Sí, dice que le duelen mucho las dos sienes desde el sábado.”
“Segunda pregunta: ¿cuando le paso la mano por el pelo o le cepillo el pelo, le duele la cabeza?”
Sofía: “Sí, el sábado cuando lo peiné, gritó del dolor. Le dije que era muy exagerado.”
“Tercera pregunta: ¿cuando está comiendo, la mandíbula se le cansa o le duele y tiene que parar de masticar?”
Sofía: “El domingo estaba comiendo el almuerzo y me dijo que la mandíbula se le estaba poniendo muy cansada. Tuvo que dejar el bistec a medias. Pensé que era el dentista que le toca esta semana.”
Nurse Salinas-Ramírez had his answer in three questions. Bilateral temporal headache, scalp pain with hair brushing, and jaw claudication (the masseter and temporalis muscles becoming ischemic during sustained chewing, forcing the patient to stop eating mid-meal) in a patient with known PMR on a steroid taper: this was a giant cell arteritis emergency.
“Señora Sofía, necesito que lleven al señor Aurelio a urgencias ahora mismo — no mañana, hoy. Le voy a llamar al servicio de urgencias de reumatología para que estén esperando. Los tres síntomas que me describió — el dolor de sienes, que le duela la cabeza al peinarse, y que la mandíbula se le canse al comer — en una persona con polimialgia pueden ser señal de que la inflamación ha llegado a las arterias de los ojos. Si eso está pasando, hay riesgo de que pierda la vista si no recibe tratamiento hoy. ¿Tienen transporte?”
(Mrs. Sofía, I need you to take Mr. Aurelio to the emergency room right now — not tomorrow, today. I am going to call the rheumatology on-call service so they will be expecting you. The three symptoms you described — temple pain, head pain when combing, jaw fatigue when chewing — in a person with polymyalgia can be a sign that the inflammation has reached the arteries of the eyes. If that is happening, there is a risk of losing vision if he does not receive treatment today. Do you have transportation?)
Sofía confirmed they had a car. Salinas-Ramírez called the rheumatology attending on call and notified the emergency department. He documented the conversation completely in the chart.
Aurelio and Sofía arrived at the emergency department two hours later. The emergency physician performed the history and examination: Aurelio confirmed bilateral temporal headache onset over three days; scalp tenderness over the bilateral temporal and occipital regions; jaw claudication during eating (the masseter and temporalis muscles were supplied by branches of the maxillary and superficial temporal arteries, both of which were GCA-affected territories); mild shoulder stiffness (the PMR component had been controlled by his maintenance prednisone). Physical examination: bilateral superficial temporal arteries were tender and cord-like on palpation (the classic “nodular, thickened, tender temporal artery” sign of GCA); no temporal artery pulse on the right. Visual fields to confrontation: intact bilaterally. Relative afferent pupillary defect (RAPD): absent bilaterally. Ophthalmology was consulted for urgent slit-lamp examination and intraocular pressure measurement: optic disc examination showed no disc edema (no AION yet), normal cup-to-disc ratio, no pallor. ESR: 104 mm/hr (from a baseline of fourteen on his maintenance prednisone — the relapse had overwhelmed his low-dose steroid). CRP: 8.8 mg/dL. Platelets: markedly elevated at 642 thousand (reactive thrombocytosis, a common finding in active GCA).
The rheumatology fellow confirmed the diagnosis of giant cell arteritis. Prednisone was immediately increased from seven-point-five milligrams per day to sixty milligrams per day, the standard high-dose induction dose for GCA without visual involvement (if there had been visual symptoms, intravenous methylprednisolone one gram per day for three days would have been started first). The temporal artery biopsy was scheduled for the following morning: biopsy results are not affected by corticosteroids started within two weeks because the granulomatous infiltration of the vessel wall takes longer than that to clear. The biopsy showed classic GCA: dense lymphocytic infiltration of the adventitia; granulomatous inflammation in the media with multinucleated giant cells; disruption and fragmentation of the internal elastic lamina (the hallmark pathological finding of GCA, representing the site of immune complex deposition and enzymatic destruction by macrophage-derived matrix metalloproteinases); intimal hyperplasia with luminal stenosis. Diagnosis confirmed: giant cell arteritis, cranial pattern.
Tocilizumab was initiated at the follow-up visit one week after discharge: one hundred sixty-two milligrams subcutaneous weekly, with a planned prednisone taper over twenty-six to fifty-two weeks per the GiACTA trial protocol. At the six-week follow-up: ESR twelve mm/hr, CRP 0.2 mg/dL, no headache, no scalp tenderness, jaw claudication resolved. Visual fields: intact bilaterally at all follow-up assessments to twelve months.
The outcome of this case depended entirely on the nurse’s phone call. The front-desk message had been “headache since Saturday, wondering if should worry.” If Salinas-Ramírez had not reviewed that message board, or had not known that headache in a PMR patient required three specific questions, or had not been able to ask those three questions in Spanish in terms Sofía could understand and respond to accurately, Aurelio would have taken Tylenol for two more days before the temporal arteries progressed to posterior ciliary artery involvement and permanent vision loss. The posterior ciliary arteries are terminal branches of the ophthalmic artery; they supply the optic nerve head; GCA vasculitis there produces AION within twenty-four to seventy-two hours of vascular insufficiency onset. There is no intervention that reverses AION once it has occurred; high-dose steroids can only prevent progression to the fellow eye.
The nurse’s three-question protocol is the standard of care for any PMR patient presenting with new headache:
Question 1: “¿El dolor de cabeza está en las sienes — a los lados de la cabeza, cerca de donde nace el pelo?” (Is the headache in the temples — the sides of the head, near where the hair begins?)
Question 2: “¿Le duele la cabeza cuando la toca con los dedos, o cuando alguien le peina o le cepilla el pelo?” (Does your head hurt when you touch it with your fingers, or when someone combs or brushes your hair?)
Question 3: “¿Cuando está masticando o comiendo, la mandíbula o los músculos de la cara se le cansan o le duelen y tiene que parar de comer?” (When you are chewing or eating, do the jaw or facial muscles get tired or hurt and do you have to stop eating?)
Any “yes” to Question 1 or 2 or 3 in a PMR patient on a steroid taper = same-day evaluation, same-day call to the rheumatology team, document every step.
Scenario 3: Concepción Vázquez-Herrera — 74 years old, Dallas, Texas
Concepción Vázquez-Herrera was a seventy-four-year-old retired pharmacist in Dallas who had been diagnosed with large vessel giant cell arteritis after a four-month workup for constitutional symptoms. The presentation had been atypical for cranial GCA: no temporal headache, no scalp tenderness, no jaw claudication, no visual symptoms. Instead: progressive fatigue over four months; eight-kilogram unintentional weight loss; bilateral shoulder and arm stiffness worse in the morning (the PMR component); bilateral subclavian bruits audible on auscultation; asymmetric blood pressure between arms (right arm 148/88, left arm 128/82, a sixteen-millimeter difference suggesting left subclavian stenosis); and left-arm fatigue when carrying groceries (early arm claudication from the left subclavian involvement).
ESR was 112 mm/hr; CRP 9.8 mg/dL; IL-6 elevated at 84 picograms per milliliter (normal <7 pg/mL); platelet count 718 thousand (reactive thrombocytosis). A temporal artery biopsy had been performed at a community hospital at the start of the workup and returned as non-diagnostic: non-specific adventitial inflammation, no giant cells, no internal elastic lamina disruption. Skip lesions — areas of normal vessel between inflamed segments — are present in temporal artery biopsies in fifteen to twenty-five percent of GCA cases, producing false-negative results; this was likely a skip-lesion negative biopsy.
PET-CT was performed: bilateral subclavian arteries showed elevated FDG uptake (SUVmax 3.2 on the right, 3.5 on the left); left common carotid artery showed uptake (SUVmax 2.8); bilateral axillary arteries showed mild uptake (SUVmax 2.1); bilateral superficial temporal arteries showed mild uptake (SUVmax 1.8, consistent with temporal arteritis contribution despite the biopsy skip lesion). The aorta and mesenteric/iliac vessels showed no focal uptake above background. Diagnosis: large vessel giant cell arteritis, bilateral subclavian and left common carotid pattern, with concurrent PMR.
Concepción was started on prednisone forty milligrams per day plus tocilizumab one hundred sixty-two milligrams subcutaneous weekly. She had been a pharmacist and understood medication mechanisms well — or believed she did. At the treatment initiation visit, clinic nurse Patricia Morales-Ríos explained the treatment plan, the subcutaneous injection technique for tocilizumab, and the monitoring schedule. She included in that explanation a specific point about CRP on tocilizumab: she told Concepción directly that her CRP would normalize within two to four weeks of starting tocilizumab, and that this was expected and did not mean the GCA had resolved. She documented this in the chart.
At four months, Concepción’s CRP was 0.3 mg/dL (from 9.8); ESR 14 mm/hr; no PMR symptoms; bilateral subclavian bruits unchanged on exam; no new cranial GCA symptoms; arm claudication resolved. The prednisone taper was at ten milligrams per day. The clinic team was pleased with the response.
Concepción stopped tocilizumab two weeks after the four-month visit. She had not called the clinic. She had reasoned: CRP was normal, ESR was normal, she felt well, the subclavian bruits were the same as before (she had looked this up and knew bruits could persist after the inflammation resolved due to structural remodeling), and she was a retired pharmacist who understood drug regimens. She concluded that the GCA was in remission and that the tocilizumab, which cost a substantial co-payment, could be stopped.
The clinical trajectory after stopping was predictable but slower than patients often expect, because tocilizumab has a terminal half-life of approximately four to seven days after the last dose; the receptor occupation is lost progressively over two to four weeks after the last injection. Six weeks after stopping: a routine lab by her cardiologist for a separate cardiac follow-up showed CRP 1.8 mg/dL (mildly elevated; the rising CRP reflecting the unblocked IL-6 receptor now being reached by IL-6 from the ongoing arterial inflammation). Her cardiologist did not know about the GCA and did not flag this to rheumatology. Ten weeks after stopping: CRP 4.6 mg/dL; bilateral shoulder stiffness had returned (PMR symptoms); mild left arm heaviness with carrying. Fourteen weeks after stopping: new bilateral temporal headache, mild; CRP 7.2 mg/dL; ESR 68 mm/hr. She called the clinic at this point.
An urgent MRA of the chest and upper extremities was ordered. Results: bilateral axillary artery stenosis (new wall thickening and mild luminal narrowing not present on the baseline PET-CT four months prior); the left subclavian showed increased wall thickening compared to the initial PET-CT; no aortic dilatation. The imaging confirmed what the clinical trajectory had implied: the granulomatous arterial inflammation had been active throughout the four months of tocilizumab treatment (the CRP had been blocked, not the disease) and structural vascular remodeling had progressed during the four months of treatment plus the fourteen weeks off treatment — approximately seven months of incompletely controlled large vessel GCA had produced new bilateral axillary stenosis.
Nurse Morales-Ríos met with Concepción and her daughter Elena at the urgent visit. Concepción was a former pharmacist — this was not a patient who needed simplified explanations. She needed the exact mechanism explained accurately.
“Concepción, entiende usted cómo funciona el tocilizumab con respecto a la proteína C reactiva?” the nurse asked. “Porque hay algo en este medicamento que es diferente de otros antiinflamatorios, y es la razón por la que la PCR normal no significa lo mismo aquí que en otras situaciones.”
Concepción: “Yo asumí que si la PCR era normal, la inflamación estaba controlada.”
“Eso es correcto con la mayoría de los tratamientos. Con los corticoides, si la PCR baja, es porque estamos suprimiendo la producción de interleucina-6 en las células inflamatorias — la propia fuente. Con el tocilizumab, no suprimimos la producción de IL-6 — bloqueamos el receptor al que se une la IL-6. El hígado produce la PCR en respuesta a la señal de IL-6. El tocilizumab bloquea el receptor en el hígado que recibe esa señal. Así que la IL-6 se sigue produciendo en las paredes de las arterias — el proceso inflamatorio continúa — pero la señal no llega al hígado porque el receptor está bloqueado por el medicamento. La PCR baja a cero porque el hígado no puede responder, no porque la inflamación en las arterias haya desaparecido. Cuando para el tocilizumab, el receptor vuelve a quedar libre en dos o tres semanas, la IL-6 que se seguía produciendo en las arterias durante todo ese tiempo ahora encuentra el receptor libre, y la PCR sube de nuevo. Lo que las imágenes ahora nos muestran es que esa inflamación en las arterias produjo cambios estructurales mientras la PCR era normal.”
(Concepción, do you understand how tocilizumab works with respect to CRP? Because there is something about this medication that is different from other anti-inflammatories, and it is the reason why normal CRP does not mean the same thing here as in other situations. / I assumed that if CRP was normal, the inflammation was controlled. / That is correct with most treatments. With corticosteroids, if CRP falls it is because we are suppressing IL-6 production in the inflammatory cells — the source itself. With tocilizumab, we do not suppress IL-6 production — we block the receptor to which IL-6 binds. The liver produces CRP in response to the IL-6 signal. Tocilizumab blocks the receptor in the liver that receives that signal. So IL-6 continues to be produced in the vessel walls — the inflammatory process continues — but the signal does not reach the liver because the receptor is blocked by the medication. CRP falls to zero because the liver cannot respond, not because the inflammation in the arteries has disappeared. When you stop tocilizumab, the receptor is unblocked within two to three weeks, the IL-6 that was being produced in the arteries all along now finds the receptor free, and CRP rises again. What the imaging now shows us is that that inflammation in the arteries produced structural changes while CRP was normal.)
Concepción was visibly frustrated — not with the nurse, but with herself. “Mi propio conocimiento de farmacología me llevó a equivocarme.” (My own pharmacology knowledge led me astray.)
“Es la trampa más común con este medicamento,” Morales-Ríos said. “La PCR que baja con tocilizumab se parece exactamente a la PCR que baja cuando la inflamación se controla con otros tratamientos. La diferencia es invisible en el análisis de sangre. Por eso el plan de doce a dieciocho meses existe: no porque el reumatólogo no confía en el laboratorio, sino porque sabemos que la PCR en este contexto no refleja la actividad de la enfermedad en las arterias.”
(It is the most common trap with this medication. The CRP that falls with tocilizumab looks exactly like the CRP that falls when inflammation is controlled with other treatments. The difference is invisible in the blood test. That is why the twelve-to-eighteen-month plan exists: not because the rheumatologist does not trust the laboratory, but because we know that CRP in this context does not reflect disease activity in the arteries.)
Tocilizumab was restarted at one hundred sixty-two milligrams SC weekly. Prednisone was increased to twenty milligrams per day to address the relapse, with a planned retaper. At eight weeks: CRP 0.2 mg/dL, ESR 11 mm/hr, no headache, bilateral shoulder stiffness resolving. MRA was scheduled at six months to reassess the axillary stenosis. The planned tocilizumab duration was extended to twenty-four months from the restart given the structural progression during the first course. At twelve months from restart: MRA showed stable axillary wall thickening without progression; no new vessel involvement; no aortic dilatation. Prednisone tapered to five milligrams per day at fourteen months from restart; targeted to zero at twenty-four months with tocilizumab; PET-CT planned at twenty months to assess for residual active vessel wall uptake before discontinuation.
Frequently asked questions
Why must prednisone continue for twelve to eighteen months in PMR even after pain resolves?
PMR pain resolves within two to four weeks of starting prednisone because prednisone suppresses IL-6-driven periarticular bursitis and synovitis through glucocorticoid receptor-mediated transrepression of NF-κB and AP-1 in macrophages and dendritic cells in the shoulder and hip periarticular tissues. This suppression requires daily prednisone at effective concentrations; the inflammatory cells resume IL-6 and other cytokine production within days of stopping. Stopping prednisone when pain resolves removes the daily suppression: NF-κB and AP-1 are no longer repressed; macrophage IL-6 production resumes; periarticular bursitis and synovitis return within two to four weeks; the patient’s pain and stiffness return at the level of the untreated disease. The ACR/EULAR 2015 guidelines recommend a minimum of twelve to eighteen months of corticosteroid therapy for PMR, with a very gradual taper from fifteen milligrams per day to zero over this period, guided by symptoms and ESR/CRP every four to eight weeks. Sixty to eighty percent of patients who taper faster than this protocol relapse within the first year. Bone protection (calcium, vitamin D, bisphosphonate if bone density is low or other risk factors present) and glucose monitoring must accompany any prolonged prednisone course. The Spanish frame: “La prednisolona no cura la polimialgia — la controla cada día que usted la toma. El dolor desapareciendo no significa que la enfermedad se fue — significa que el medicamento está bloqueando la inflamación. El plan correcto es bajarla muy poco a poco durante doce a dieciocho meses mientras verificamos que la inflamación no regrese.” (Prednisone does not cure polymyalgia — it controls it every day you take it. The pain disappearing does not mean the disease is gone — it means the medication is blocking the inflammation. The correct plan is to lower it very gradually over twelve to eighteen months while verifying the inflammation does not return.)
What are the three GCA symptoms that require same-day evaluation in a PMR patient?
The three symptoms that distinguish a GCA emergency from an ordinary headache in a PMR patient are: (1) new temporal headache — headache located in the temples or bilateral frontal region in a patient with known PMR; (2) scalp tenderness — pain when touching the scalp, brushing, or combing the hair, particularly over the temporal and occipital regions; (3) jaw claudication — fatigue and pain in the masseter and temporalis muscles that develops during sustained chewing and resolves with rest, caused by GCA vasculitis of the facial artery and superficial temporal artery reducing perfusion to the chewing muscles. Any of these three symptoms in a PMR patient requires same-day rheumatology notification; all three together require same-day emergency evaluation. The urgency is driven by anatomy: posterior ciliary artery GCA vasculitis produces anterior ischemic optic neuropathy causing acute monocular vision loss within twenty-four to seventy-two hours; fifteen to twenty-five percent of untreated cases develop bilateral AION. High-dose prednisone forty to sixty milligrams per day must be started the same day GCA is clinically suspected — biopsy confirmation is not required before treatment, and the biopsy remains positive for up to two weeks after starting steroids. The Spanish frame: “Los tres síntomas que me debe reportar el mismo día: dolor de cabeza en las sienes, que le duela el cuero cabelludo al peinarse, o que la mandíbula se le canse o duela al masticar. Cualquiera de los tres: llámeme ese día. Los tres juntos: vaya a urgencias. Estos síntomas pueden significar que la inflamación ha afectado las arterias de los ojos y el riesgo de perder la vista es real.” (The three symptoms you must report to me the same day: headache in the temples, pain in the scalp when combing, or jaw fatigue or pain when chewing. Any of the three: call me that day. All three together: go to the emergency room. These symptoms can mean the inflammation has affected the eye arteries and the risk of losing vision is real.)
Why does CRP normalize under tocilizumab and why does normal CRP not indicate GCA remission?
CRP is produced exclusively by hepatocytes in response to IL-6 signaling: IL-6 binds the IL-6 receptor on hepatocytes → JAK1/JAK2 activation → STAT3 phosphorylation → CRP gene transcription. Tocilizumab blocks the IL-6 receptor with high affinity, preventing IL-6 from binding its receptor on hepatocytes regardless of how much IL-6 the arterial wall inflammatory cells are producing. CRP falls to near-zero within seven to fourteen days of starting tocilizumab — not because IL-6 production in the vessel wall has been suppressed, but because the hepatocyte receptor is occupied and cannot receive the IL-6 signal. The granulomatous inflammation in the arterial media continues: CD4+ T cells and macrophages continue producing IL-6, TNF, and IL-17; giant cells continue destroying the internal elastic lamina; intimal hyperplasia and luminal stenosis continue to progress. This dissociation between CRP and vessel wall disease activity is unique to IL-6 receptor blockade; it is not seen with prednisone (which suppresses upstream IL-6 production and therefore reduces both the inflammation and its CRP marker). When tocilizumab is stopped at CRP normalization — which occurs in all patients on adequate dosing — the drug clears in two to four weeks; the IL-6 receptor is unoccupied; the ongoing vessel wall IL-6 finds its unblocked receptor; CRP rises within three to eight weeks of stopping; GCA symptoms and vascular damage progression resume. ACR 2021 recommends a minimum twelve months of tocilizumab for GCA; large vessel GCA warrants eighteen to twenty-four months. Vascular imaging (MRA, CT angiography, or PET-CT) — not CRP — is the correct tool for assessing whether large vessel GCA disease is structurally quiescent. The Spanish frame: “La PCR normal con tocilizumab no significa que las arterias se curaron — significa que el medicamento está bloqueando la señal que refleja la inflamación. La inflamación en las paredes de las arterias puede continuar aunque la PCR sea normal. El plan es continuar el medicamento el tiempo indicado y hacer imágenes de las arterias para verificar que la enfermedad está realmente en remisión antes de considerar parar.” (Normal CRP with tocilizumab does not mean the arteries healed — it means the medication is blocking the signal that reflects the inflammation. Inflammation in the artery walls can continue even when CRP is normal. The plan is to continue the medication for the indicated time and do artery imaging to verify the disease is truly in remission before considering stopping.)
What is the relationship between polymyalgia rheumatica and giant cell arteritis and why are they managed as a spectrum?
PMR and GCA are two clinical expressions of the same granulomatous large vessel vasculitis: CD4+ Th1 and Th17 cells activated by dendritic cells in the arterial adventitia produce interferon-gamma (activating macrophages and granuloma formation) and IL-17 (promoting neutrophil recruitment and vessel remodeling); macrophages in the media produce IL-6 in massive quantities, driving the systemic acute phase response (ESR, CRP, constitutional symptoms); giant cells form from macrophage fusion in the media; matrix metalloproteinases from these macrophages destroy the internal elastic lamina; intimal hyperplasia causes luminal stenosis and occlusion. In PMR, this process is predominantly expressed in periarticular bursae and synovia of the shoulder and hip girdles, producing stiffness and aching without (yet) clinically significant transmural arteritis. In cranial GCA, the same process dominates the superficial temporal, posterior ciliary, ophthalmic, and occipital arteries. In large vessel GCA, it dominates the subclavian, axillary, common carotid, aorta, and vertebral arteries. These phenotypes overlap: fifteen to twenty-five percent of PMR patients eventually develop GCA; PET-CT shows subclinical large vessel uptake in twenty-five to forty percent of PMR patients without clinical GCA symptoms; cranial and large vessel GCA co-occur in approximately thirty to forty percent of GCA patients. The same treatment — prednisone plus or minus tocilizumab depending on severity — is used across the PMR-GCA spectrum; the dose and duration differ by phenotype. Managing them as a spectrum means the nurse always asks a PMR patient about cranial GCA symptoms at every visit and every phone contact, because PMR is not a stable disease that stays in the periarticular bursa: it is a systemic large vessel inflammatory disease that can transition to arteritic involvement of end-organ vessels at any time, including during an apparently well-controlled steroid taper. The Spanish frame: “La polimialgia y la arteritis son la misma enfermedad mostrándose en lugares diferentes del cuerpo. Por eso siempre le preguntamos sobre los síntomas de la cabeza aunque usted tenga solo polimialgia controlada — la inflamación puede afectar las arterias en cualquier momento, incluso cuando el dolor de la polimialgia está bien controlado.” (Polymyalgia and arteritis are the same disease showing itself in different parts of the body. That is why we always ask about head symptoms even when you only have controlled polymyalgia — the inflammation can affect the arteries at any time, even when the polymyalgia pain is well controlled.)
What are the key Spanish phrases for GCA symptom surveillance, prednisone side effect counseling, and tocilizumab injection teaching in PMR and GCA clinic?
For the three-question GCA surveillance protocol for PMR patients at every visit and phone contact: “Tengo tres preguntas rápidas que le voy a hacer siempre que hablem os, porque con la polimialgia es importante saber de inmediato si aparecen ciertos síntomas. Primera: ¿ha tenido algún dolor de cabeza nuevo desde la última cita, especialmente en las sienes? Segunda: ¿le ha dolido la cabeza cuando se ha peinado o tocado el cuero cabelludo? Tercera: ¿cuando come, la mandíbula o los músculos de la cara se le han cansado o han dolido y ha tenido que parar de masticar? Si la respuesta a cualquiera de estas tres preguntas es sí, necesitamos verlo o hablar con el reumatólogo ese mismo día.” (I have three quick questions I am going to ask you every time we speak, because with polymyalgia it is important to know immediately if certain symptoms appear. First: have you had any new headache since the last visit, especially in the temples? Second: has your head hurt when you combed your hair or touched your scalp? Third: when eating, have your jaw or facial muscles gotten tired or hurt and made you stop chewing? If the answer to any of these three questions is yes, we need to see you or speak with the rheumatologist the same day.) For prednisone side effect counseling, distinguishing manageable from urgent effects: “La prednisolona puede causar varios efectos secundarios que son frecuentes y manejables con ajustes: puede subir el azúcar en sangre — si tiene diab etes, monitoree con más frecuencia y háganos saber si los números suben de lo normal; puede causar que le cueste más trabajo dormirse o mantenerse dormido; puede causar un pequeño aumento de peso y retención de líquidos; puede cambiar el ánimo, causando que se sienta más irritable o con energía extra. Todos estos los podemos manejar. Los efectos que requieren que nos llame ese día: fiebre mayor de 38 grados con escalofríos (la prednisolona suprime el sistema inmune y una infección puede progresar rápidamente); visión borrosa o pérdida de visión en un ojo (esto es urgente — llame al 911 si pierde visión de repente); dolor de pecho o dificultad para respirar. Lo que no debe hacer: parar la prednisolona sola en casa. Si los efectos son muy molestos, llámenos para hablar cómo ajustar la dosis.” (Prednisone can cause several side effects that are frequent and manageable with adjustments: it can raise blood sugar — if you have diabetes, monitor more frequently and let us know if numbers go above normal; it can make it harder to fall asleep or stay asleep; it can cause a small weight gain and fluid retention; it can change mood, making you feel more irritable or with extra energy. All of these we can manage. Effects that require calling us the same day: fever above 38 degrees with chills (prednisone suppresses the immune system and an infection can progress quickly); blurry vision or loss of vision in one eye (this is urgent — call 911 if you suddenly lose vision); chest pain or difficulty breathing. What you should not do: stop prednisone on your own at home. If effects are very bothersome, call us to discuss how to adjust the dose.) For tocilizumab injection site rotation and storage: “El tocilizumab se guarda en el refrigerador. Antes de inyectarse, sáquelo del refrigerador treinta minutos antes para que llegue a temperatura ambiente — la inyección duela menos cuando no está fría. Los sitios de inyección son: la parte baja del abdomen (evitando dos pulgadas alrededor del ombligo), la parte exterior del muslo, o la parte de atrás del brazo si alguien le puede ayudar. Cambie de sitio cada semana — no inyecte en la misma zona dos semanas seguidas. Dé la inyección el mismo día de la semana cada semana. Si olvida un día, déla ese mismo día si se acuerda a tiempo; si ya pasó el día, omita esa semana y continúe la siguiente. Nunca dé dos inyecciones la misma semana. Si nota una reacción en el sitio de la inyección — enrojecimiento, protuberancia, o dolor que dura más de cuarenta y ocho horas — llámenos.” (Tocilizumab is stored in the refrigerator. Before injecting, take it out thirty minutes beforehand to reach room temperature — the injection hurts less when it is not cold. Injection sites are: the lower abdomen (avoiding two inches around the belly button), the outer thigh, or the back of the arm if someone can help. Change sites every week — do not inject in the same area two weeks in a row. Give the injection the same day of the week every week. If you forget a day, give it that same day if you remember in time; if the day has passed, skip that week and continue the next. Never give two injections the same week. If you notice a reaction at the injection site — redness, lump, or pain lasting more than forty-eight hours — call us.)